Consumer brand funding
rounds, since 2020,
in one ledger.

How to read
these counts.

The funding side of the consumer world tells a quieter story than the acquisition side, and in some ways a more honest one. An acquisition is a verdict. A funding round is a bet. When I read the 174 consumer brand rounds tracked through September 20, 2026, what I see is a market that has stopped writing lottery tickets and started underwriting businesses again.

This page is built to sit alongside the companion 2026 M&A tracker. If you want to know what buyers are paying for finished brands, read that one. This one is about the money going in earlier: who is funding the next Poppi or Olipop, at what stage, and in which categories. The two together give you the full arc, from first institutional check to strategic exit.

I have raised for brands, sat across the table from the funds writing these checks, and operated the kind of company that shows up on both lists. So I am less interested in the headline round sizes than in the shape of the flow: where capital concentrates, which stages are getting funded, and what that tells a founder deciding whether to raise at all in 2026.

The 2026 consumer
funding wave,
on one page.

Here is the running log of consumer brand rounds, newest first, starting with this year's. Earlier years, back to 2020, have their own pages. It covers named raises of $3M or more, from seed checks to nine-figure growth rounds. Undisclosed and sub-$3M rounds are left out, so treat the list as a floor on the real activity, not a ceiling.

Food, drink, and
wellness are taking
most of the money.

Food and beverage is not close to a fair fight in 2026. It is the single most-funded consumer category by a wide margin, and inside it the money keeps landing on the same few ideas: functional beverages, high-protein everything, non-alcoholic drinks, and better-for-you snacking. The Ryl Company, Brami, Khloud, Waterdrop, OLIPOP, Crazy Mountain, and a long tail of energy and hydration brands all raised inside the window. If you are pitching a founder-brand in food or drink with a real health angle, the capital is there.

Wellness is the clear second, and it is where the most interesting money sits. Supplements, peptides, gut health, hormone health, and women's health pulled in some of the largest rounds of the year, including WHOOP at $575M and Nourish at $100M. Beauty, which dominates the acquisition tracker, is quieter on the funding side: steady Series A and B rounds rather than mega-raises, because the best beauty brands are getting bought before they ever need a growth round. Apparel and pet round out the map, thinner but real, with Rhoback, Selkirk, Loyal, and Ollie all landing capital.

The missing middle
is the whole story.

The stage distribution is the tell. Strip out the handful of nine-figure growth rounds and the center of gravity sits at seed and Series A, in the $3M to $20M band. That is early money, and it is being deployed carefully. The generic funding rounds with no named stage are mostly bridge and extension checks, existing investors topping up brands that are working rather than new syndicates piling into a hot name.

The growth end is thin and selective. WHOOP at $575M, OLIPOP raising $200M, Oishii at $150M, Starface and Blank Street at $105M, Nourish and Loyal at $100M, Waterdrop north of EUR 100M: these are scaled businesses with real revenue, not stories. There is almost nothing in the awkward middle, the $40M to $90M Series C that used to be routine in 2021. Founders should read that gap plainly. Capital is available to get you started, and available to scale a proven winner, but the money to paper over a business that has not found its economics has largely left the building.

Specialist funds set
the terms. Celebrity
money buys a launch.

Two kinds of money dominate the 2026 rounds. The first is the consumer-specialist fund: CAVU, VMG Partners, Selva Ventures, Collaborative Fund, Greycroft, BFG Partners, Prelude Growth, and a deepening bench of firms that only do food, beverage, beauty, and wellness. These are the investors who understand gross margin and velocity, and they are the ones setting terms on the priced rounds.

The second, and the more telling, is strategic and celebrity capital. Corporate venture arms like Unilever Ventures and Dabur Ventures are showing up early, effectively option-buying future acquisitions. And the celebrity money is everywhere: Paul George in a hydration brand, Patrick Mahomes in Throne Sport Coffee, Khloe Kardashian's Khloud, Maria Shriver and Patrick Schwarzenegger in Mosh, Ben Stiller's soda. Some of that is signal and some is noise. A famous cap table gets you a launch, not a business. The founders who will still be raising in 2027 are the ones who took the celebrity check for the distribution it unlocks, then built the unit economics that let a specialist fund lead the next round.

Raise for a milestone,
and mind the exit
math the whole way.

If you are a founder deciding whether to raise in 2026, the tracker says three things. First, category matters more than it has in years. A credible food, beverage, or wellness brand with a health angle can find early capital right now. A me-too brand in a crowded lane cannot. Second, raise for a milestone, not for runway. The money is flowing to seed and Series A rounds that fund a specific proof point, and to growth rounds that scale a proven engine. The raise-to-survive round is the hardest one to close in this market.

Third, know which game you are playing. The realistic outcome for most brands is a strategic sale in the low hundreds of millions, not a decacorn, which is the entire argument of the companion M&A tracker. That ceiling should shape how much you raise and at what valuation. Every dollar you take at a fantasy price narrows the pool of buyers who can clear it later. The founders getting funded well in 2026 are building for the buyer who is actually writing checks, and financing the brand to get there without pricing themselves out of their own exit.

The window for consumer capital is open, but it is a narrower, more disciplined window than the last cycle. Build the brand a fund can underwrite, raise for the milestone in front of you, and keep an eye on the exit math the whole way. If you are raising, or deciding whether to, the Partner tier is the engagement built for that decision, the work page has the relevant case studies and the inquiry form is the fastest way to a conversation.

The natural next step after a raise closes is the acquisition conversation: the acquirer map tracks who is actually buying consumer brands right now and at what multiple, and the wider set of eight living trackers, funding, exits, ownership, shutdowns and more, sits on The Index.

What the ledger is
made of, by category.

508 rounds logged between 2020 and 2026, split by category. The counts below add up to that total.

How the category mix
shifted, year by year.

Each cell is a category's share of what was logged that year. Shares compare fairly across years in a way raw totals cannot. The last line gives each year's total, which measures how much was found.

How big the
disclosed rounds were.

Bands over the 403 rounds logged that disclosed a size. A round with no disclosed size is left out of every band.

Who led the
most rounds.

Lead investors by distinct rounds logged, top 15. 35 of the rounds logged name the investor only as undisclosed or not disclosed, and those are left out of this table.

Earlier years, on
their own pages.

Each year before 2026 has its own page with every entry for that year, month by month, and its own category mix.

Questions founders ask
me most about raising
in the 2026 market.

A note on sources: this tracker leans on the consumer deal reporting that Drew Fallon publishes in his Making Cents newsletter (worth a follow on X), plus the running deal flow from CPG Wire. Individual round figures are drawn from company announcements, SEC Form D filings, and trade press including BevNET, NOSH, Beauty Independent, BeautyMatter, WWD, and Modern Retail. Amounts reported but not officially disclosed are labeled as such. The interpretation, and any errors in it, are mine.